Viral infections after renal transplantation

American Journal of Kidney Diseases

Volumn 37, Issue 4, 2001, Pages 659-676

  Smith, Stephen R ^a   Butterly, David W ^a   Alexander, Barbara D ^a   Greenberg, Arthur ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Herpesviruses; Influenza; Kaposi's sarcoma (KS); Parainfluenza; Parvovirus; Polyoma virus; Posttransplant lymphoproliferative disorder (PTLD); Renal transplantation; Respiratory syncytial virus (RSV)

Indexed keywords

VIRUS DNA;

ADENOVIRUS; ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS; DIAGNOSTIC TEST; EPSTEIN BARR VIRUS; HERPES SIMPLEX; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLUENZA VIRUS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MORTALITY; PARAINFLUENZA VIRUS; PARVOVIRUS; POLYMERASE CHAIN REACTION; POLYOMA VIRUS; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VARICELLA ZOSTER VIRUS; VIREMIA; VIRUS INFECTION;

EID: 0035059968     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(01)80114-1     Document Type: Review

References (103)

1. Infection in organ-transplant recipients
2. A comparative study of herpes simplex infections in renal transplant and leukemic patients
3. Chronic intraoral herpes simplex infection in renal transplant recipients
4. Herpes simplex esophagitis after renal transplantation
5. Disseminated herpes simplex infection: Primary lesions in urinary bladder and successful treatment with foscarnet sodium
6. Herpes simplex virus hepatitis after solid organ transplantation in adults
7. CNS diseases associated with varicella zoster virus and herpes simplex virus infection. Pathogenesis and current therapy
8. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections
9. Prevention of recurrent herpes infection after renal transplantation by low-dose oral acyclovir
10. Varicella in children with renal transplants
11. Chickenpox in adult renal transplant recipients
12. Primary varicella in adult renal transplant recipients: A report of three cases plus a review of the literature
13. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients
14. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients
15. Neurologic complications of the reactivation of varicella-zoster virus
16. Acute viral infections
17. Varicella zoster in a transplant program: Experience with 15 cases and 70 contacts
18. Varicella and zoster in children after kidney transplantation: Long-term results of vaccination
19. Attenuated varicella virus vaccine in children with renal transplants
20. Acyclovir halts progression of herpes zoster in immunocompromised patients
21. Current management of varicella zoster virus infections
22. Outcome of chickenpox in 66 pediatric renal transplant recipients
23. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil
24. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children
25. Risk factors for postherpetic neuralgia
26. Epstein-Barr virus infection
27. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies
28. Post-transplantation lymphoproliferative disease
29. Immunosuppression - A contributory factor in lymphoma formation
30. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders
31. Treatment of organ transplant-related lymphoma
32. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy
33. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3
34. Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: Is prophylaxis necessary?
35. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain
36. The clinical significance of cytomegaloviral inclusions in the allograft kidney
37. Does cytomegalovirus cause glomerular injury in renal allograft recipients?
38. Cytomegalovirus infection - An etiological factor for rejection? A prospective study in 242 renal transplant patients
39. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
40. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
41. The role of PCR in the diagnosis and management of CMV in solid organ recipients. What is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?
42. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients
43. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation
44. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: Implications for donor selection
45. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients
46. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
47. Drug therapy: Antiviral drugs
48. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus anti- body-positive renal transplant recipients. A randomized controlled trial
49. Control of cytomegalovirus-associated morbidity in renal tranplant patients using intensive monitoring and either preemptive or deferred therapy
50. Clinical practice guidelines: Prevention of cytomegalovirus disease after renal transplantation
51. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients
52. A prospective study of human herpesvirus-6 infection in renal transplantation
53. Human herpesvirus-6 infection in renal allografts: Retrospective immunohistochemical study in Japanese recipients
54. Human herpesvirus-6 in transplantation: An emerging pathogen
55. Human herpesvirus-6 infection in liver transplant recipients
56. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation
57. Severe allograft dysfunction after OKT3-induced human herpesvirus-6 reactivation
58. Primary human herpesvirus 7 infection: A comparison of human herpesvirus 7 and human herpesvirus 6 infections in children
59. Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection
60. Human herpesvirus-8 infection in hemodialysis patients from northern Italy
61. Kaposi's sarcoma: The most common tumor after renal transplantation in Saudi Arabia
62. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: Report of 13 cases
63. Risk of Kaposi's sarcoma-associated herpesvirus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients
64. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients
65. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients
66. Kaposi's sarcoma in transplant recipients
67. Orthomyxoviral and paramyxoviral infections in transplant patients
68. Influenza A in immunocompromised patients
69. Influenza B in transplant patients
70. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols. Mycophenolate versus azathioprine
71. Efficacy and safety of the neuraminidase idase inhibitor zanamivir in the treatment of influenza virus infections
72. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients
73. Adenoviruses in the immunocompromised host
74. Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient
75. Human polyoma virus-associated interstitial nephritis in the allograft kidney
76. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients
77. Testing for polyomavirus type BK DNA in plasma to identify renalallograft recipients with viral nephropathy
78. Progressive multifocal leukoencephalopathy in a renal transplant patient diagnosed by JCV-specific DNA amplification and an intrathecal humoral immune response to recombinant virus protein 1
79. Human parvovirus B19 infection in organ transplant recipients
80. Parvovirus B19 infection-related complications in renal transplant recipients: Treatment with intravenous immunoglobulin
81. Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro
82. Glucocorticoids induce Kaposi's sarcoma cell proliferation through the regulation of transforming growth factor-beta
83. Differential effects of nerve growth factor and dexamethasone on herpes simplex virus type 1 oriL- and oriS-dependent DNA replication in PC12 cells
84. Evidence for a functional glucocorticoid responsive element in the Epstein-Barr virus genome
85. Infectious disease complications of renal transplantation
86. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
87. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center
88. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
89. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
90. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at three years
91. Impact of cytomegalovirus infection on organ transplant recipients
92. Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A
93. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone
94. Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine
95. Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon
96. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
97. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection
98. The evaluation of renal transplant candidates: Clinical practice guidelines
99. Severe varicella associated with steroid use
100. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era
101. The effect of the dosage of steroids on the incidence of cytomegalovirus infections in renal transplant recipients
102. The appearance of Kaposi sarcoma during corticosteroid therapy
103. Five cases of Kaposi's sarcoma in kidney graft recipients: Possible influence of the immunosuppressive therapy